ASCO 2025 – Braftovi breaks new ground
The Breakwater study hits on overall survival with "unprecedented" data.
ASCO 2025 preview – KRAS challengers assemble
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
ASCO 2025 preview – Kura looks similar to Syndax
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
ASCO 2025 preview – patritumab hangs in the balance
Herthena-Lung02 data are an ASCO shocker.
ASCO 2025 preview – Merus tops Bicara
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
ASCO 2025 preview – Itovebi strengthens its first-line claim
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
Enliven seeks its reverse merger payday
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
CDH17 becomes flavour of the month
Antibody-drug conjugates hitting this target abound.
AACR 2025 – BioNTech sees its first combo glimmers
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
AACR 2025 – a requiem for Roche's TIGIT
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
